Skip to main content
Dermapharm Holding SE logo

Dermapharm Holding SE — Investor Relations & Filings

Ticker · DMP ISIN · DE000A2GS5D8 LEI · 5299009F0KNZINQQQK37 F Manufacturing
Open in API
Filings indexed 245 across all filing types
Latest filing 2025-11-13 Interim / Quarterly Rep…
Country DE Germany
Listing F DMP

About Dermapharm Holding SE

https://ir.dermapharm.de/index-EN.php

Dermapharm Holding SE is a manufacturer of branded pharmaceuticals and healthcare products, with a focus on the patent-free segment. The company operates an integrated business model that encompasses the entire value chain, including in-house research and development, production, and distribution. A dedicated pharmaceutical sales force manages the marketing and sales of its brand products. Dermapharm maintains a diversified portfolio concentrated on selected therapeutic areas, allowing it to establish strong market positions. The company operates several production, development, and distribution sites to support its operations and international expansion.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM STATEMENT Q3 2025' and contains detailed financial tables, including a consolidated statement of financial position, segment performance analysis, and a report on economic position for the nine-month period ending September 30, 2025. It provides substantive financial data and analysis rather than just an announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-13 English
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Dermapharm Holding SE stating that they will publish their quarterly/interim financial reports on a future date (November 13, 2025). It provides links to where the reports will be available. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore falls under the Report Publication Announcement (RPA) category.
2025-11-05 English
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or a person closely associated with them. It explicitly lists the name of the person, the nature of the transaction (Acquisition), the financial instrument (Share), and the price/volume details. This aligns perfectly with the definition of 'Director's Dealing' (DIRS).
2025-11-03 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Annual Report Classification · 100% confidence The document is the 'Jahresabschluss' (Annual Financial Statement) for Dermapharm Aktiengesellschaft for the fiscal year 2024. It includes the balance sheet, profit and loss statement, notes, and the independent auditor's report (Bestätigungsvermerk). As it contains the full financial statements and audit report for the fiscal year, it qualifies as an Annual Report (10-K equivalent in the German context). FY 2024
2025-09-03 German
Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter
Earnings Release Classification · 100% confidence The document is an announcement from Dermapharm Holding SE regarding their H1 2025 financial results. It provides key highlights, segment performance, and confirms full-year guidance. Crucially, it explicitly states that the full report is available for download via a link, which aligns with the 'Menu vs Meal' rule for a Report Publication Announcement (RPA). H1 2025
2025-08-26 English
Half-yearly financial report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT 2025' and contains comprehensive financial data, including a group results table, interim management report, and consolidated financial statements for the period ending 30 June 2025. It is a full interim report, not an announcement or a summary, and therefore fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.